JP2022504435A5 - - Google Patents
Info
- Publication number
- JP2022504435A5 JP2022504435A5 JP2021518962A JP2021518962A JP2022504435A5 JP 2022504435 A5 JP2022504435 A5 JP 2022504435A5 JP 2021518962 A JP2021518962 A JP 2021518962A JP 2021518962 A JP2021518962 A JP 2021518962A JP 2022504435 A5 JP2022504435 A5 JP 2022504435A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- interferon
- beta
- product according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743449P | 2018-10-09 | 2018-10-09 | |
| US62/743,449 | 2018-10-09 | ||
| PCT/US2019/055167 WO2020076809A1 (en) | 2018-10-09 | 2019-10-08 | Combination of ibudilast and interferon-beta and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504435A JP2022504435A (ja) | 2022-01-13 |
| JP2022504435A5 true JP2022504435A5 (enExample) | 2022-10-13 |
Family
ID=68343518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518962A Pending JP2022504435A (ja) | 2018-10-09 | 2019-10-08 | イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10946071B2 (enExample) |
| EP (1) | EP3863628B1 (enExample) |
| JP (1) | JP2022504435A (enExample) |
| CN (1) | CN112770748A (enExample) |
| CA (1) | CA3115269A1 (enExample) |
| ES (1) | ES2973119T3 (enExample) |
| WO (1) | WO2020076809A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024528731A (ja) | 2021-07-26 | 2024-07-30 | メディシノバ・インコーポレイテッド | 眼癌転移を予防するためのイブジラスト |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8562198A (en) | 1998-08-10 | 2000-03-06 | Kyorin Pharmaceutical Co. Ltd. | Remedies for multiple sclerosis |
| US20060093578A1 (en) | 2004-11-04 | 2006-05-04 | Kyorin Pharmaceutical Co., Ltd. | Method and composition for treating multiple sclerosis |
| WO2006063048A2 (en) | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| MX2008014971A (es) * | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| EP2277515A1 (en) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| PE20140872A1 (es) * | 2010-12-07 | 2014-08-09 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple |
| ES2716865T3 (es) * | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
-
2019
- 2019-10-08 EP EP19794366.5A patent/EP3863628B1/en active Active
- 2019-10-08 JP JP2021518962A patent/JP2022504435A/ja active Pending
- 2019-10-08 ES ES19794366T patent/ES2973119T3/es active Active
- 2019-10-08 CA CA3115269A patent/CA3115269A1/en active Pending
- 2019-10-08 US US16/596,278 patent/US10946071B2/en active Active
- 2019-10-08 CN CN201980065787.0A patent/CN112770748A/zh active Pending
- 2019-10-08 WO PCT/US2019/055167 patent/WO2020076809A1/en not_active Ceased